
- NeurAxis (NRXS) specializes in neuromodulation therapies, targeting chronic abdominal pain in pediatric and adult patients.
- NRXS exhibits exceptional technical momentum with shares trading at new all-time highs.
- The stock is up more than 300% over the past 52 weeks and maintains a 100% “Buy” opinion from Barchart.
- Healthcare sector tailwinds support NRXS, yet prudent risk management is advised given volatility and speculative characteristics.